Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Update

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 38,700,000 shares, a growth of 36.1% from the April 30th total of 28,430,000 shares. Based on an average trading volume of 12,300,000 shares, the short-interest ratio is currently 3.1 days. Approximately 3.4% of the shares of the stock are sold short.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently made changes to their positions in TEVA. Barclays PLC lifted its position in shares of Teva Pharmaceutical Industries by 31.7% in the third quarter. Barclays PLC now owns 427,595 shares of the company’s stock valued at $7,705,000 after acquiring an additional 102,848 shares in the last quarter. KBC Group NV lifted its position in shares of Teva Pharmaceutical Industries by 43.2% in the fourth quarter. KBC Group NV now owns 37,163 shares of the company’s stock valued at $819,000 after acquiring an additional 11,220 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its stake in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after purchasing an additional 33,277 shares during the last quarter. Capital Insight Partners LLC increased its stake in Teva Pharmaceutical Industries by 190.1% in the fourth quarter. Capital Insight Partners LLC now owns 40,617 shares of the company’s stock valued at $895,000 after purchasing an additional 26,617 shares during the last quarter. Finally, DAVENPORT & Co LLC increased its stake in Teva Pharmaceutical Industries by 3.8% in the fourth quarter. DAVENPORT & Co LLC now owns 381,488 shares of the company’s stock valued at $8,408,000 after purchasing an additional 13,811 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Bank of America boosted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Finally, Truist Financial started coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a “buy” rating and a $25.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $24.50.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA traded up $0.32 on Monday, hitting $17.10. The company had a trading volume of 5,588,665 shares, compared to its average volume of 12,556,339. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $22.80. The business has a 50 day moving average of $15.52 and a 200 day moving average of $17.37. The company has a market cap of $19.38 billion, a PE ratio of -11.79, a PEG ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the prior year, the business earned $0.48 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. As a group, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.